Aldeyra Therapeutics (NASDAQ:ALDX) Upgraded to “Buy” at ValuEngine
ALDX has been the subject of a number of other research reports. Zacks Investment Research downgraded Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 14th. Cantor Fitzgerald set a $33.00 price objective on Aldeyra Therapeutics and gave the stock a “buy” rating in a report on Tuesday, June 25th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $26.79.
Shares of ALDX stock traded up $0.68 on Tuesday, reaching $5.58. The company’s stock had a trading volume of 452,135 shares, compared to its average volume of 379,555. Aldeyra Therapeutics has a 12-month low of $4.31 and a 12-month high of $16.70. The company has a market capitalization of $135.96 million, a P/E ratio of -3.12 and a beta of 0.61. The stock’s 50 day simple moving average is $5.04 and its 200-day simple moving average is $6.82.
Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE grew its position in Aldeyra Therapeutics by 139.4% during the fourth quarter. Bank of America Corp DE now owns 12,181 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 7,093 shares during the last quarter. Deutsche Bank AG raised its position in Aldeyra Therapeutics by 17.0% in the 4th quarter. Deutsche Bank AG now owns 39,658 shares of the biotechnology company’s stock worth $328,000 after purchasing an additional 5,753 shares during the period. BNP Paribas Arbitrage SA purchased a new position in Aldeyra Therapeutics in the 1st quarter worth $40,000. Rhumbline Advisers raised its position in Aldeyra Therapeutics by 17.3% in the 1st quarter. Rhumbline Advisers now owns 27,183 shares of the biotechnology company’s stock worth $245,000 after purchasing an additional 4,010 shares during the period. Finally, National Asset Management Inc. lifted its stake in Aldeyra Therapeutics by 69.4% in the first quarter. National Asset Management Inc. now owns 27,006 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 11,066 shares during the last quarter. Hedge funds and other institutional investors own 61.26% of the company’s stock.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Read More: Coverage Ratio
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.